Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 2/20 | 0.32 |
| ▸ | FNTA | P49354 | 3/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144605 | 0.87 | FDPS (0.50) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL24469373 | 0.84 | CA2 (0.37) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL687243 | 0.79 | FDPS (0.47) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL16855741 | 0.79 | FDPS (0.47) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL412533 | 0.79 | FDPS (0.47) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL19387807 | 0.78 | FDPS (0.53) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL889928 | 0.78 | FDPS (0.53) | FDPSBLMTDP1BTN3A1CA2 | |
| Triphosphate SCHEMBL15555988 | 0.78 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL18714 | 0.78 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL10862597 | 0.77 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020007070-A1 | CRYSTAL FORM, PREPARATION METHOD, AND APPLICATION OF 4'-SUBSTITUTED NUCLEOSIDE | 河南真实生物科技有限公司 | 2020-01-09 | — | — | WO | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | FDPS 618/4885BLM 1558/4885TDP1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.